GHRP-6, GHRP-2, and Ipamorelin: GH Secretagogue Research Landscape

Background

Growth hormone-releasing peptides (GHRPs) are synthetic small peptides that activate the growth hormone secretagogue receptor (GHS-R1a) — the same receptor that native ghrelin binds. Unlike GHRH-class analogs (sermorelin, CJC-1295), which amplify hypothalamic GHRH signaling, ghrelin receptor agonists bypass the hypothalamus and act directly on pituitary somatotrophs and CNS circuits.

This receptor targeting is pharmacologically distinct and produces different off-target profiles across GHRP generations. Ipamorelin was developed specifically to minimize those off-targets.

Receptor pharmacology

GHS-R1a is a class A GPCR expressed on:

• Pituitary somatotrophs (GH release)
• Hypothalamic arcuate nucleus (appetite regulation via NPY/AgRP neurons)
• Vagal afferents and enteric nervous system
• Cardiovascular tissue

Activation couples primarily to Gαq/11, elevating intracellular calcium through the PLC–IP3 pathway. This mechanism is mechanistically different from GHRH-class Gαs/cAMP signaling — which is why GHRP + GHRH combinations are synergistic rather than additive in GH release assays.

Generation-by-generation overview

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂)

• First major synthetic GHS to enter research
• Strongly activates GHS-R1a
• Off-targets: notable prolactin elevation, cortisol elevation via ACTH, and strong appetite stimulation through hypothalamic NPY/AgRP
• Use case: studies where hunger/feeding signaling is the endpoint (e.g., NPY expression) or legacy comparator

GHRP-2 (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH₂)

• Higher potency for GH release than GHRP-6
• Less appetite stimulation than GHRP-6
• Still elevates prolactin and cortisol, though generally less than GHRP-6
• Use case: GH-release reference where stronger pulse is desired

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂)

• Developed in the late 1990s as a selective GHS-R1a agonist
• Comparable GH-release potency to GHRP-6
• Minimal effect on prolactin, cortisol, and ACTH in published studies
• Clean off-target profile makes it the most common research reference for isolated GH-axis studies
• Molecular weight: ~711 Da (small pentapeptide)

What laboratories typically study

• GH release kinetics — acute pulse amplitude, duration, desensitization kinetics in pituitary cell lines and primary somatotrophs
• Receptor bias — G protein vs β-arrestin recruitment differences between generations
• Combination pharmacology — GHRP + GHRH synergy (see /blog/cjc-1295-ipamorelin-mechanism)
• Appetite/feeding research — specifically GHRP-6 for hypothalamic NPY/AgRP activation studies
• Cortisol/prolactin off-target mapping — why ipamorelin is preferred when isolating GH effects
• Cardiovascular research — GHS-R1a is expressed in cardiac tissue; some GHRPs show direct cardioprotective effects in ischemia-reperfusion models independent of GH

Handling and quality

• All supplied as lyophilized powder (typical format 5 mg)
• Store lyophilized at -20°C, light-protected
• Reconstitute with sterile/bacteriostatic water shortly before use
• Reconstituted stability ~4 weeks at 2–8°C
• Verify by HPLC (≥99.0%) with MS identity; obtain batch COA

Related reading

• /research/ipamorelin — ipamorelin compound profile
• /compare/ipamorelin-vs-cjc-1295 — GHRP vs GHRH class comparison
• /compare/ipamorelin-vs-sermorelin — comparative class framing
• /blog/cjc-1295-ipamorelin-mechanism — synergy mechanism
• /blog/sermorelin-vs-cjc-1295-ghrh-analog-research — GHRH class parallel
• /category/muscle-growth-research — broader category

RUO disclaimer

For laboratory research use only. Not for human consumption. Combinations and protocols require institutional justification and oversight.